<DOC>
	<DOCNO>NCT01548014</DOCNO>
	<brief_summary>The purpose evaluate whether administration infliximab 12 week interval supplementary VSL # 3 effective least similar efficacy compare conventional administration infliximab 8 week interval .</brief_summary>
	<brief_title>The Effect Probiotic Preparation ( VSL # 3 ) Plus Infliximab Children With Crohn 's Disease</brief_title>
	<detailed_description>The purpose study evaluate supplementation VSL # 3 improve treatment outcome pediatric Crohn 's patient treat infliximab every 12 week .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Pediatric patient diagnose severe Crohn 's disease require infliximab treatment confirm diagnostic Crohn 's disease clinical , endoscopic histological finding patient proven infliximab antibody</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Crohn 's disease</keyword>
	<keyword>VSL # 3</keyword>
	<keyword>infliximab</keyword>
</DOC>